Catheter ablation has become as the first-line treatment for patients with symptomatic atrial fibrillation (AF). As the cornerstone of catheter ablation for AF, the safety and efficacy of circumferential pulmonary vein isolation (CPVI) have been confirmed. However, for persistent AF, especially for long-standing persistent AF (LSPAF), the recurrence rate is still high. Whether the ethanol infusion (EI) into the vein of Marshall (EI-VOM) and linear ablation could improve the success rate remains controversial.
The SINUS study is a prospective, multicenter, randomized trial, which is designed to compare the efficacy and safety between CPVI with modified linear ablation (CPVI-MLA) and CPVI only for the treatment of LSPAF.
1. Patients with symptomatic LSPAF refractory to at least one antiarrhythmic drug; LSPAF will be defined as a sustained AF episode lasting ≥ 1 year;
AF duration 1-3 years;
Age 18 - 75 years;
Left atrial diameter (LAD) 43-55 mm on long axis parasternal view;
Paroxysmal atrial fibrillation;
Persistent AF lasting < 1 year or >3 years;
Left atrial thrombosis;
Patients with a history of catheter ablation for AF;
The First Affiliated Hospital with Nanjing Medical University
Lead sponsor